Variagenics presses on with cancer diagnostics:
This article was originally published in Clinica
Variagenics has moved a step closer to its aim of developing molecular diagnostic tests predictive of the response of solid tumours to chemotherapy. The Cambridge, Massachusetts firm has begun its first clinical study to identify genetic markers for chemotherapeutic toxicity. The retrospective study will involve the genetic analysis of over 100 patients who have experienced severe side effects following 5-fluorouracil chemotherapy for colorectal cancer.